36/100

Nkarta Inc

NKTXCell Therapy

📋

Analyst Summary

✓ VERIFIED2026-04-11

Nkarta Inc (NKTX) is the lead sponsor of 4 active clinical trials listed on ClinicalTrials.gov^[3], including 2 Phase 2^[1], 4 Phase 1^[2].

No Form 4 insider filings for NKTX were recorded at the SEC in the past 30 days^[4].

Sources

ClinicalTrials.gov (2026-04-11) ↗
ClinicalTrials.gov (2026-04-11) ↗
ClinicalTrials.gov (2026-04-11) ↗
SEC EDGAR · 0001787400 (2026-04-11) ↗

🔬

Clinical Trials

NCT04623944Relapsed/Refractory AML, AML, Adult, MDS, Refractory Myelodysplastic Syndromes

Source ↗

clinicaltrials_gov · Retrieved 2026-04-11

NCT05020678Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma, Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma, Large-cell Lymphoma

Source ↗

clinicaltrials_gov · Retrieved 2026-04-11

NCT06557265Lupus Nephritis, Primary Membranous Nephropathy

Source ↗

clinicaltrials_gov · Retrieved 2026-04-11

NCT06733935Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

Source ↗

clinicaltrials_gov · Retrieved 2026-04-11

👤

Insider Activity

0 filings

Source ↗

sec_edgar · Retrieved 2026-04-11

Not financial advice. BiotechSigns profiles are AI-generated from verified public sources (ClinicalTrials.gov, SEC EDGAR) and are for informational purposes only. Always do your own due diligence before making investment decisions.

Score Breakdown

Score Trend

2026-04-132026-06-02

Signal Summary

PDUFA Dates0

Insider Filings1

Clinical Trials1

Sector Peers (Cell Therapy)

ATRAAtara Biotherapeutics

VORVor Biopharma

IOVAIovance Biotherapeutics

FATEFate Therapeutics